George Davis, the Executive Vice President and Chief Legal Officer of Biomarin Pharmaceutical Inc (BMRN, Financial), has sold 24,602 shares of the company on March 28, 2024, according to a recent SEC filing. The transaction was executed at an average price of $88.34 per share, resulting in a total value of $2,173,352.68.
Biomarin Pharmaceutical Inc is a biotechnology company focused on the development and commercialization of innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio includes products and product candidates that target various diseases and conditions, including genetic, neurological, and metabolic diseases.
Over the past year, George Davis has sold a total of 49,366 shares of Biomarin Pharmaceutical Inc and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of 19 insider sells and no insider buys over the same timeframe.
Shares of Biomarin Pharmaceutical Inc were trading at $88.34 on the day of the insider's recent transaction, giving the company a market capitalization of $16.43 billion. The price-earnings ratio of the stock stands at 98.98, which is above the industry median of 29.5 but below the company's historical median price-earnings ratio.
According to the GuruFocus Value, with a price of $88.34 and a GF Value of $105.47, Biomarin Pharmaceutical Inc has a price-to-GF-Value ratio of 0.84, indicating that the stock is considered Modestly Undervalued.
The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates provided by Morningstar analysts.
The insider trend image above reflects the recent selling activity by insiders at Biomarin Pharmaceutical Inc, which may be of interest to investors monitoring insider behaviors as an indicator of company performance or future stock price movements.
The absence of a GF Value image indicates that the current valuation image is not available at the time of writing. Investors are encouraged to refer to the latest data on the GuruFocus website for updated valuation insights.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
